News
XRTX
2.902
-1.30%
-0.038
XORTX’s Breakthrough Study on Kidney Disease
TipRanks · 2d ago
XORTX’s Research Offers New Hope for ADPKD
TipRanks · 2d ago
Weekly Report: what happened at XRTX last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at XRTX last week (0408-0412)?
Weekly Report · 04/15 11:14
XORTX Therapeutics Boosts Board with Biotech Pro
TipRanks · 04/08 12:08
XORTX Gears Up for Spring 2024 Investor Conferences
TipRanks · 04/08 11:59
XORTX Therapeutics Appoints Industry Leader to Board
TipRanks · 04/08 11:57
XORTX Therapeutics Engages Investors in Spring Events
TipRanks · 04/08 11:48
XORTX WELCOMES NEW MEMBER TO THE BOARD OF DIRECTORS
Reuters · 04/08 11:30
Weekly Report: what happened at XRTX last week (0401-0405)?
Weekly Report · 04/08 11:19
Xortx Therapeutics Reports Stable Finances
TipRanks · 04/04 10:57
Weekly Report: what happened at XRTX last week (0325-0329)?
Weekly Report · 04/01 11:16
XORTX Therapeutics Inc <XRTX.V> expected to post a loss of 60 cents a share - Earnings Preview
XORTX Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview. The average analyst rating on the shares is "strong buy" for the period ending December 31 2023. Wall Street's median 12-month price target for the company is $12.15.
Reuters · 03/29 21:07
XORTX Welcomes New Expert to Clinical Board
TipRanks · 03/27 15:27
XORTX Therapeutics Expands Clinical Advisory Board
TipRanks · 03/27 10:37
Weekly Report: what happened at XRTX last week (0318-0322)?
Weekly Report · 03/25 11:19
XORTX Gears Up for Kidney Disease Trial Advancements
TipRanks · 03/20 10:58
XORTX Therapeutics Advances Kidney Disease Program
Xortx Therapeutics (TSE:XRTX) achieved U.S. Orphan Drug Designation for its XRx-008 program for ADPKD in 2023. The company is expected to complete a pivotal registration clinical trial for their lead program in 2024.
TipRanks · 03/19 10:37
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Science Applications International Corporation shares dipped 10.7% to $127.29 on Monday. The company reported financial fourth-quarter EPS below estimates. Canoo Inc. Shares surged 95% after the US Department of Commerce approved its Oklahoma City facility as a Foreign Trade Zone.
Benzinga · 03/18 18:37
Weekly Report: what happened at XRTX last week (0311-0315)?
Weekly Report · 03/18 11:18
More
Webull provides a variety of real-time XRTX stock news. You can receive the latest news about Xortx Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About XRTX
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.